A case of Aripiprazole and extra pyramidal side effects

Abstract

This is a case report of a 56-year-old lady who was admitted to a psychiatric ward because she was showing a plethora of positive and negative symptoms of schizophrenia. She has a positive history of mental illness; her mother had a diagnosis of schizophrenia. The patient did not have any medical history of relevance and was not taking any medication. She was commenced on Aripiprazole and after 5 weeks developed disabling extra-pyramidal side effects. On discontinuation of Aripiprazole, the side effects subsided and disappeared quickly. According to the authors' knowledge, this is the first case of a patient developing extra-pyramidal side effects following treatment with Aripiprazole, not previously exposed to other antipsychotic, and with no co-morbid medical conditions. The authors suggest titrating Aripiprazole slowly.

An update of safety of clinically used atypical antipsychotics

“…However, aripiprazole mostly triggered akathisia/restlessness (possibly representing a condition of subjective non-motor akathisia) [40]. Notably, there are anecdotal reports of aripiprazole-induced EPS, mostly at the highest doses [41][42]. It is possible that the reported induction of EPS by aripiprazole may relate to a dose-dependent loss of D 2 receptor functional selectivity.…”

Do partial agonists cause akathisia: the role of the mental health nurse who prescribes

“…There have been case studies published describing clinical observations of akathisia, following the initiation of Aripiprazole (Pinninti & Mago 2006, Salmoiraghi & Odiyoor 2006). Trials investigating short‐, medium‐ and long‐term effects of partial agonists, like Aripiprazole, against other anti‐psychotics, have also reported the presence of akathisia.…”

Molecular modeling studies of 1,2,4-triazine derivatives as novel h-DAAO inhibitors by 3D-QSAR, docking and dynamics simulations

“…Over the past few decades, all typical and second-generation antipsychotics that act on the D2 dopamine receptor ( e.g. , perphenazine, 6 clozapine, 7 olanzapine, 8 risperidone, 9 ziprasidone 10 and aripiprazole 11 ) have caused considerable metabolic and negative side effects. 12 In addition, only a small number of patients have completely responded to these currently available antipsychotics, which cannot satisfy the requirements of patients with different etiologies.…”